Pharmacokinetic and Safety Study of Bismuth Potassium Citrate Formulations in Healthy Subjects
Drugs in R&D · 2024
DOI: 10.1007/s40268-024-00455-9 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Drugs in R&D, 2024. Verfasst von Hong-Yu Luo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, School of Pharmacy, Phase I Clinical Trial Centre, The Affiliated Changsha Central Hospital, Hengyang Medical School, Univers…. Hauptthemen laut MEDLINE: Bismuth, Organometallic Compounds. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Changsha Central Hospital Affiliated to University of South China Foundation of key Program, Scientific Research Fund of Hunan Provincial Education Department, Hunan Provincial Natural Science Foundation of China.
Abstract (Originalsprache)
BACKGROUND: Potassium bismuth citrate is a gastric mucosal protector and a key drug for treating peptic ulcers. OBJECTIVE: To evaluate the pharmacokinetic characteristics and safety of 120-mg bismuth potassium citrate formulations administered orally under fasting conditions in healthy Chinese subjects. METHOD: A single-center open two-cycle trial was conducted on 12 healthy subjects who received a single oral dose of 120 mg of bismuth potassium citrate. The plasma concentration of bismuth was determined using a validated inductively coupled plasma mass spectrometry (ICP‒MS) method. The pharmacokinetic parameters, including maximum serum concentration (Cmax) and area under the curve concentration-time curve (AUC0-t and AUC0-∞), and safety were evaluated via noncompartment analysis. RESULTS: The ratios of the least square geometric mean ratio between the test (T) and reference (R) formulations for Cmax, AUC0-t, and AUC0-∞ were 44.8%, 55.5%, and 64.4%, respectively; the bilateral 95% confidence intervals (Cis) for these parameters were 20.2-99.6%, 24.1-127.5%, and 23.7-175.0%, respectively, and the non-inferior limits for these parameters were 169.4%, 198.8%, and 200.5%, respectively. The upper limits of the one-sided 97.5% confidence interval for the least squares geometric mean ratio (T/R) were lower than the non-inferior limits. No serious adverse reactions or adverse reactions leading to detachment were observed among the subjects. CONCLUSION: The concentration of bismuth in the blood of healthy subjects in the T formulation was not greater than that in the R formulation. Similarly, the safety of oral administration of 120 mg of bismuth potassium citrate formulations to healthy subjects was good. The trial registration number (TRN) was [2018] 013, 6 December 2018.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, School of Pharmacy, Phase I Clinical Trial Centre, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha, China.
- Affiliated Changsha Hospital of Hunan Normal University (The Fourth Hospital of Changsha), Changsha, China.
- Department of Pharmacy, School of Pharmacy, Phase I Clinical Trial Centre, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha, China. 89206346@qq.com.
- Hunan Warrant Pharmaceutical Co., Ltd., Changsha, China.
Förderung
- Changsha Central Hospital Affiliated to University of South China Foundation of key Program
- Scientific Research Fund of Hunan Provincial Education Department
- Hunan Provincial Natural Science Foundation of China
Zitieren
APA
Luo, H. Y., Xu, S. G., Gao, L. C., Long, H. Z., Zhou, Z. W., Li, F. J., Dai, S. M., Hu, J. D., Su, Y., & Cheng, Y. (2024). Pharmacokinetic and Safety Study of Bismuth Potassium Citrate Formulations in Healthy Subjects. Drugs in R&D. https://doi.org/10.1007/s40268-024-00455-9
Vancouver
Luo HY, Xu SG, Gao LC, Long HZ, Zhou ZW, Li FJ, et al. Pharmacokinetic and Safety Study of Bismuth Potassium Citrate Formulations in Healthy Subjects. Drugs in R&D. 2024. doi:10.1007/s40268-024-00455-9
BibTeX
@article{Luo2024,
author = {Luo, Hong-Yu and Xu, Shuo-Guo and Gao, Li-Chen and Long, Hui-Zhi and Zhou, Zi-Wei and Li, Feng-Jiao and Dai, Shang-Ming and Hu, Jin-Da and Su, Yu and Cheng, Yan},
title = {Pharmacokinetic and Safety Study of Bismuth Potassium Citrate Formulations in Healthy Subjects},
journal = {Drugs in R&D},
year = {2024},
doi = {10.1007/s40268-024-00455-9}
}
EUVIMED